Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 2

Mechanisms for Activation of Beige Adipose Tissue in Humans

Philip Kern · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT04666636

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 35–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 2
Target enrollment
65
US sites recruiting
1
Study start
December 7, 2020
Record last updated
July 7, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients

Being studied: Placebo; Mirabegron; Mirabegron 50 MG; Mirabegron 100 mg

Conditions: PreDiabetes

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • BMI 27-45
  • prediabetes (A1c 5.7-6.4)
  • impaired fasting glucose or impaired glucose tolerance

Exclusion Criteria

  • diabetes
  • chronic use of anti-diabetic medication
  • acute or chronic inflammatory condition
  • unstable medical condition
  • cancer
  • renal insufficiency
  • any contraindication for Mirabegron
  • BMI >45

Recruiting US locations

  • University of Kentucky

    Lexington, KY 40536

    Site contact: Zach Leicht · 859-218-1397 · zachary.leicht@uky.edu

Study contacts (from the official record)

  • Zach Leicht · 859-218-1397 · zachary.leicht@uky.edu
  • Philip Kern, MD · 859-218-1394 · pake222@uky.edu
All diabetes studies in Kentucky →
Mechanisms for Activation of Beige Adipose Tissue in Humans (NCT04666636) | Bored Studies